Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Remy Varga

Artificial intelligence gives new hope for sufferers of severe heart problem

April 20, 2023
New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.
Read Transcript

New artificial intelligence software can improve the diagnosis of severe aortic stenosis by 72 per cent and could potentially change the lives of about 50,000 Australians with the life-threatening condition who are misdiagnosed each year.

The EchoSolv diagnostic software identified more than twice as many cases of the disease, a narrowing of the heart valve, than humans, according to research conducted by St Vincent’s hospitals in Sydney and Melbourne that compiled more than 9000 studies.

St Vincent‘s Hospital Cardiology and Heart Lung Program director Michael Feneley said the research found 218 human-found patients with the condition compared to 442. “It turns out we humans only found about half of the patients with severe aortic stenosis in the sample and the AI found the rest,” he said.

Currently cardiologists diagnose severe aortic stenosis by manually reviewing dozens of echocardiograms, which are pictures of the heart, to identify about a dozen common problems.

About half of severe conditions and more than two-thirds of cases in women are missed under current diagnostic methods.

University of Notre Dame professor Geoff Strange, the principal investigator on the research, said in Australia there were about 100,000 patients with a treatable form of the disease and about a quarter of a million with some kind of valvular disease. “We’re treating about 10,000 – that’s a big deficit of patients,” he said.

Prof Strange said the EchoSolv addressed misdiagnosis by reviewing measurements collected during a cardiac ultrasound, the most common procedure to detect valvular heart disease, and painting a picture of the condition of the heart.

“It gives a probability output in about 1.5 seconds for the clinician to know whether the patient in front of them has a high probability of severe aortic stenosis,” he said.

Prof Strange said the study had identified a number of biases in diagnosis including around symptoms and gender, with the condition going undetected in women compared to men.

“The reason this is overcome by artificial intelligence is because it doesn’t have any unconscious bias,” he said.

Merilyn Oaks, 81, was diagnosed with severe aortic stenosis in December 2020 and last week had her aortic valve replaced with a catheter.

Use of the EchoSolve technology could have detected her condition earlier but Ms Oaks said she was grateful for technological advancements that allowed her more time with her seven grandkids.

“Only a few of the older ones actually know I’ve had this procedure but they’re very keen for me to be around for as long as I possibly can,” she said.

“For me that’s a very good thing.”

Prof Feneley has been treating Ms Oaks and said she was the type of patient who could benefit from the EchoSolve and save her from undergoing invasive diagnostic procedures.

“I had to do quite an invasive procedure on her,” he said.

“I put an ultrasound probe down the oesophagus so I could get closer to the heart valve and managed to get an image of the valve where I can actually measure how narrow it was directly with an image.”

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 20 April 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

New artificial intelligence software can improve the diagnosis of severe aortic stenosis by 72 per cent and could potentially change the lives of about 50,000 Australians with the life-threatening condition who are misdiagnosed each year.

The EchoSolv diagnostic software identified more than twice as many cases of the disease, a narrowing of the heart valve, than humans, according to research conducted by St Vincent’s hospitals in Sydney and Melbourne that compiled more than 9000 studies.

St Vincent‘s Hospital Cardiology and Heart Lung Program director Michael Feneley said the research found 218 human-found patients with the condition compared to 442. “It turns out we humans only found about half of the patients with severe aortic stenosis in the sample and the AI found the rest,” he said.

Currently cardiologists diagnose severe aortic stenosis by manually reviewing dozens of echocardiograms, which are pictures of the heart, to identify about a dozen common problems.

About half of severe conditions and more than two-thirds of cases in women are missed under current diagnostic methods.

University of Notre Dame professor Geoff Strange, the principal investigator on the research, said in Australia there were about 100,000 patients with a treatable form of the disease and about a quarter of a million with some kind of valvular disease. “We’re treating about 10,000 – that’s a big deficit of patients,” he said.

Prof Strange said the EchoSolv addressed misdiagnosis by reviewing measurements collected during a cardiac ultrasound, the most common procedure to detect valvular heart disease, and painting a picture of the condition of the heart.

“It gives a probability output in about 1.5 seconds for the clinician to know whether the patient in front of them has a high probability of severe aortic stenosis,” he said.

Prof Strange said the study had identified a number of biases in diagnosis including around symptoms and gender, with the condition going undetected in women compared to men.

“The reason this is overcome by artificial intelligence is because it doesn’t have any unconscious bias,” he said.

Merilyn Oaks, 81, was diagnosed with severe aortic stenosis in December 2020 and last week had her aortic valve replaced with a catheter.

Use of the EchoSolve technology could have detected her condition earlier but Ms Oaks said she was grateful for technological advancements that allowed her more time with her seven grandkids.

“Only a few of the older ones actually know I’ve had this procedure but they’re very keen for me to be around for as long as I possibly can,” she said.

“For me that’s a very good thing.”

Prof Feneley has been treating Ms Oaks and said she was the type of patient who could benefit from the EchoSolve and save her from undergoing invasive diagnostic procedures.

“I had to do quite an invasive procedure on her,” he said.

“I put an ultrasound probe down the oesophagus so I could get closer to the heart valve and managed to get an image of the valve where I can actually measure how narrow it was directly with an image.”

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 20 April 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by The Australian, published on April 20, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Picture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt Call
July 1, 2026

Next generation CAR T-cell therapy for cancer

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.

Read More
Picture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale Cohen
July 1, 2026

Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
November 15, 2024

Professor Alex Brown in conversation with Professor Jason Kovacic

At the 2024 Sohn Hearts & Minds Conference, we heard from Professor Alex Brown in conversation with Professor Jason Kovacic about Indigenous heart health and genomics.

Read More

A/Professor Tim Sargeant | 2024 Sohn Hearts & Minds Conference

Associate Professor Tim Sargeant has been at SAHMRI (South Australian Health and Medical Research Institute) in Adelaide where he studies the role of lysosomes in Alzheimer’s disease.

Read More
July 1, 2026

Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Read More
Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.
July 1, 2026

A new approach to Parkinson’s Disease

Exploring nerve stimulation as a potential treatment.

Read More
Dr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds Conference
July 1, 2026

Revealing what drives PSP

Mapping the biological changes behind progressive supranuclear palsy in the brain.

Read More
Picture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer Snaith
July 1, 2026

Advancing treatment options for type 1 diabetes

Improving blood glucose and reducing insulin needs.

Read More
Picture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish King
July 1, 2026

Solving the genetic causes of autoimmune diseases

Mapping hundreds of risk markers to better understand how these diseases develop and progress

Read More
July 1, 2026

The Future of Pain Management

Enhancing healthcare professionals' ability to deliver better pain management, now and into the future.

Read More
July 1, 2026

Harnessing the power of stem cell technology

Developing cell therapies for patients with blood diseases

Read More
Picture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki Negishi
July 1, 2026

Protecting the heart when every minute matters

Investigating a new treatment to reduce heart damage after heart attacks

Read More
Picture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio Vittorio
July 1, 2026

Targeting the drivers of cancer growth

Exploring how extrachromosomal DNA (ecDNA) drives cancer growth, spread and treatment resistance.

Read More
July 1, 2026

Improving the diagnosis of muscle disorders using advanced genetic testing

Focused on improving the efficiency and accuracy of diagnosing muscle disorders.

Read More